Shattuck Labs (STTK) Provides Company Update and Announces SL-325
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/31/2026
- Wall Street dips as spiking crude prices revive fears of inflation, rate hike
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
- Energy stocks rally as fresh U.S.-Iran attacks drive oil prices higher
- BofA turns S&P 500 signals from red to yellow: What to buy now
Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway
October 1, 2024 6:30 AM EDTInterim clinical data for SL-172154 in combination with azacitidine in TP53 mutant (TP53m) acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (HR-MDS) showed only modest improvement in median overall survival compared to azacitidine monotherapy benchmarks; further development of SL-172154 discontinued  Â
 Prioritization to focus on SL-325, a first-in-class antagonist antibody to DR3, the receptor for TL1A, intended for clinical development in inflammatory bowel disease (IBD); IND filing expected in Q3 2025
 SL-172154 associated restructuring expected to extend cash runway into 2027
 Company to host investor... More
